19 July 2021For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when…
15 July 2021
21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Whilst valproate (valproic acid/sodium valproate) is…
Medicine Compliance Aid Stability
Tablets e/c 250mg, 500mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Store in airtight container. Max 7 days in MCA.
22 November 2022
Capsules e/c 150mg, 300mg, 500mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable for MCA as preparations are hygroscopic which can affect release profile.
2 March 2015
Lactation Safety Information
Carbamazepine; Appropriate second generation antipsychotic
Significant published evidence of safety in breastfeeding indicates small amounts in breast milk
Monitor infant for jaundice, bruising, and bleeding
MHRA states that it should not used in women of child bearing age unless Pregnancy Prevention Programme is in place, and only if other treatments are ineffective or not tolerated. For this reason, carbamazepine is preferred first-line in breastfeeding (see summary)
26 July 2021